Prognostic significance of FT3 levels in hypertrophic cardiomyopathy patients with HFpEF
ObjectiveThis study sought to identify key prognostic factors in patients with hypertrophic cardiomyopathy (HCM) and heart failure with preserved ejection fraction (HFpEF), emphasizing the prognostic role of free triiodothyronine (FT3) levels.Research design and methodsThis retrospective cohort stud...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2025.1546309/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849231563001167872 |
|---|---|
| author | Zhen-Yu Yang Zhi-Yuan Zhang Wei-Jie Zhang Da Liu Fu-Shi Piao Xiangyu Yan Fang-Tao Shi Min Yang Jing Chen Sheng-song Zhu Hong-Hou He Pei-Hong Wu Cheng Qian Min Lin Jun-Qing Feng Chun-jin Lai |
| author_facet | Zhen-Yu Yang Zhi-Yuan Zhang Wei-Jie Zhang Da Liu Fu-Shi Piao Xiangyu Yan Fang-Tao Shi Min Yang Jing Chen Sheng-song Zhu Hong-Hou He Pei-Hong Wu Cheng Qian Min Lin Jun-Qing Feng Chun-jin Lai |
| author_sort | Zhen-Yu Yang |
| collection | DOAJ |
| description | ObjectiveThis study sought to identify key prognostic factors in patients with hypertrophic cardiomyopathy (HCM) and heart failure with preserved ejection fraction (HFpEF), emphasizing the prognostic role of free triiodothyronine (FT3) levels.Research design and methodsThis retrospective cohort study enrolled 992 HCM-HFpEF patients from two Chinese medical centers between 2009 and 2019, excluding those with thyroid-affecting medications or disorders. Data on demographic and clinical variables, including FT3, were analyzed using univariate and multivariate Cox regression, Kaplan–Meier (KM) survival analysis, and restricted cubic spline (RCS) analysis to explore prognostic factors and FT3's nonlinear predictive value.ResultsAge, atrial fibrillation, and NT-proBNP levels significantly influenced prognosis, while FT3 emerged as an independent predictor of all-cause mortality and cardiac transplantation (P < 0.001). Patients with lower FT3 exhibited poorer long-term outcomes, with RCS identifying a critical threshold of 2.885 pg/ml (P-non-linear < 0.05).ConclusionsFT3 is a robust prognostic marker in HCM-HFpEF patients, supporting its integration into risk stratification. Clinicians should monitor FT3 levels, though intervention efficacy requires further prospective validation. |
| format | Article |
| id | doaj-art-6227c6d5faeb4f759a87a95d9ae46764 |
| institution | Kabale University |
| issn | 2297-055X |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj-art-6227c6d5faeb4f759a87a95d9ae467642025-08-21T05:27:09ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2025-08-011210.3389/fcvm.2025.15463091546309Prognostic significance of FT3 levels in hypertrophic cardiomyopathy patients with HFpEFZhen-Yu Yang0Zhi-Yuan Zhang1Wei-Jie Zhang2Da Liu3Fu-Shi Piao4Xiangyu Yan5Fang-Tao Shi6Min Yang7Jing Chen8Sheng-song Zhu9Hong-Hou He10Pei-Hong Wu11Cheng Qian12Min Lin13Jun-Qing Feng14Chun-jin Lai15Cardiac Surgery Department, The Peoplès Hospital of Anyang City, Anyang, Henan, ChinaDepartment of Plastic and Burn Surgery, National Key Clinical Construction Specialty, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, ChinaDepartment of Cardiology, the First Hospital of Hebei Medical University, Graduate School of Hebei Medical University, Shijiazhuang, Hebei, ChinaShenzhen Third People's Hospital, Shenzhen, ChinaDepartment of Cardiology, Peking University Shenzhen Hospital, Shenzhen, ChinaInstitute of Disaster and Emergency Medicine, Tianjin University, Tianjin, ChinaCardiac Surgery Department, The Peoplès Hospital of Anyang City, Anyang, Henan, ChinaDepartment of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaDepartment of Cardiology, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, ChinaInstitute of Disaster and Emergency Medicine, Tianjin University, Tianjin, ChinaDepartment of Cardiology, the First Hospital of Hebei Medical University, Graduate School of Hebei Medical University, Shijiazhuang, Hebei, ChinaDepartment of Cardiology, the First Hospital of Hebei Medical University, Graduate School of Hebei Medical University, Shijiazhuang, Hebei, ChinaDepartment of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital, Beijing, ChinaDivision of Cardiac Arrhythmia, Cardiac and Vascular Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong, ChinaCardiac Surgery Department, The Peoplès Hospital of Anyang City, Anyang, Henan, China0Department of Cardiology, Dongguan Tai-xin Hospital, Dongguan, ChinaObjectiveThis study sought to identify key prognostic factors in patients with hypertrophic cardiomyopathy (HCM) and heart failure with preserved ejection fraction (HFpEF), emphasizing the prognostic role of free triiodothyronine (FT3) levels.Research design and methodsThis retrospective cohort study enrolled 992 HCM-HFpEF patients from two Chinese medical centers between 2009 and 2019, excluding those with thyroid-affecting medications or disorders. Data on demographic and clinical variables, including FT3, were analyzed using univariate and multivariate Cox regression, Kaplan–Meier (KM) survival analysis, and restricted cubic spline (RCS) analysis to explore prognostic factors and FT3's nonlinear predictive value.ResultsAge, atrial fibrillation, and NT-proBNP levels significantly influenced prognosis, while FT3 emerged as an independent predictor of all-cause mortality and cardiac transplantation (P < 0.001). Patients with lower FT3 exhibited poorer long-term outcomes, with RCS identifying a critical threshold of 2.885 pg/ml (P-non-linear < 0.05).ConclusionsFT3 is a robust prognostic marker in HCM-HFpEF patients, supporting its integration into risk stratification. Clinicians should monitor FT3 levels, though intervention efficacy requires further prospective validation.https://www.frontiersin.org/articles/10.3389/fcvm.2025.1546309/fullHCM-HFpEFprognosisFT3thyroid functionall-cause mortalitycardiac transplantation |
| spellingShingle | Zhen-Yu Yang Zhi-Yuan Zhang Wei-Jie Zhang Da Liu Fu-Shi Piao Xiangyu Yan Fang-Tao Shi Min Yang Jing Chen Sheng-song Zhu Hong-Hou He Pei-Hong Wu Cheng Qian Min Lin Jun-Qing Feng Chun-jin Lai Prognostic significance of FT3 levels in hypertrophic cardiomyopathy patients with HFpEF Frontiers in Cardiovascular Medicine HCM-HFpEF prognosis FT3 thyroid function all-cause mortality cardiac transplantation |
| title | Prognostic significance of FT3 levels in hypertrophic cardiomyopathy patients with HFpEF |
| title_full | Prognostic significance of FT3 levels in hypertrophic cardiomyopathy patients with HFpEF |
| title_fullStr | Prognostic significance of FT3 levels in hypertrophic cardiomyopathy patients with HFpEF |
| title_full_unstemmed | Prognostic significance of FT3 levels in hypertrophic cardiomyopathy patients with HFpEF |
| title_short | Prognostic significance of FT3 levels in hypertrophic cardiomyopathy patients with HFpEF |
| title_sort | prognostic significance of ft3 levels in hypertrophic cardiomyopathy patients with hfpef |
| topic | HCM-HFpEF prognosis FT3 thyroid function all-cause mortality cardiac transplantation |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2025.1546309/full |
| work_keys_str_mv | AT zhenyuyang prognosticsignificanceofft3levelsinhypertrophiccardiomyopathypatientswithhfpef AT zhiyuanzhang prognosticsignificanceofft3levelsinhypertrophiccardiomyopathypatientswithhfpef AT weijiezhang prognosticsignificanceofft3levelsinhypertrophiccardiomyopathypatientswithhfpef AT daliu prognosticsignificanceofft3levelsinhypertrophiccardiomyopathypatientswithhfpef AT fushipiao prognosticsignificanceofft3levelsinhypertrophiccardiomyopathypatientswithhfpef AT xiangyuyan prognosticsignificanceofft3levelsinhypertrophiccardiomyopathypatientswithhfpef AT fangtaoshi prognosticsignificanceofft3levelsinhypertrophiccardiomyopathypatientswithhfpef AT minyang prognosticsignificanceofft3levelsinhypertrophiccardiomyopathypatientswithhfpef AT jingchen prognosticsignificanceofft3levelsinhypertrophiccardiomyopathypatientswithhfpef AT shengsongzhu prognosticsignificanceofft3levelsinhypertrophiccardiomyopathypatientswithhfpef AT honghouhe prognosticsignificanceofft3levelsinhypertrophiccardiomyopathypatientswithhfpef AT peihongwu prognosticsignificanceofft3levelsinhypertrophiccardiomyopathypatientswithhfpef AT chengqian prognosticsignificanceofft3levelsinhypertrophiccardiomyopathypatientswithhfpef AT minlin prognosticsignificanceofft3levelsinhypertrophiccardiomyopathypatientswithhfpef AT junqingfeng prognosticsignificanceofft3levelsinhypertrophiccardiomyopathypatientswithhfpef AT chunjinlai prognosticsignificanceofft3levelsinhypertrophiccardiomyopathypatientswithhfpef |